Credit Suisse Maintains Outperform on PTC Therapeutics, Raises Price Target to $58

Credit Suisse maintains PTC Therapeutics (NASDAQ:PTCT) with a Outperform and raises the price target from $54 to $58.

Benzinga · 11/13/2019 13:19

Credit Suisse maintains PTC Therapeutics (NASDAQ:PTCT) with a Outperform and raises the price target from $54 to $58.